Viral vector systems are crucial in delivering therapeutic genetic material for gene and cell therapy in clinical settings. With new progress in viral vector-based gene therapies, healthcare professionals and pharmacists must stay informed and apply appropriate biosafety precautions when handling these products. Comprehensive guidelines covering biosafety measures for every viral vector-based gene therapy, including storage, preparation, administration, and disposal, remain scarce. As viral vector-based gene therapy advances rapidly, it is critical to equip healthcare professionals with the expertise to safely manage these agents in a clinical setting.
Methods:
As gene therapies become more integrated into mainstream medicine, with 43 cell and gene therapy products approved as of 2025, pharmacists, nurses, and caregivers face new safety challenges when handling these therapies. While guidelines such as United States Pharmacopeia (USP) 797 and USP 800 provide a foundation for handling viral vector-based gene therapies, no single resource consolidates all biosafety considerations for healthcare professionals. This review provides an overview of the viral vector-based gene therapy landscape. It compiles best practices from various sources to establish a potential standardized approach to guide safe handling procedures for viral vector systems in a healthcare setting.
Discussion:
By adopting the biosafety strategies outlined in this article, healthcare staff and pharmacists can safely manage viral vectors while developing standard operating procedures tailored to their specific clinical environments. Implementing these measures will support the continued advancement of gene therapy while ensuring the safety of healthcare providers, patients, and the environment.
GhoshS, BrownAM, JenkinsC, CampbellK. Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges. Appl Biosaf, 2020; 25(1):7–18; doi: 10.1177/1535676019899502
2.
EisenmanD, DeboldS, RiddleJ. A changing world in gene therapy research: Exciting opportunities for medical advancement and biosafety challenges. Appl Biosaf, 2021; 26(4):179–192; doi: 10.1089/apb.2021.0020
3.
CondreayJP, KostTA, MickelsonCA. Emerging conisderations in virus-based gene transfer systems. In: Biological Safety Principles and Practices. Wiley: 2017; p. 741.
4.
StoneD. Novel viral vector systems for gene therapy. Viruses, 2010; 2(4):1002–1007; doi: 10.3390/v2041002
5.
LundstromK. Viral vectors in gene therapy: Where do we stand in 2023? Viruses, 2023; 15(3); doi: 10.3390/v15030698
6.
Wooley DPaBKB. Biological Safety Principles and Practices. Wiley; 2017.
7.
RamamoorthM, NarvekarA. Non viral vectors in gene therapy- an overview. J Clin Diagn Res, 2015; 9(1):Ge01–Ge06; doi: 10.7860/jcdr/2015/10443.5394
8.
JollyD. Viral vector systems for gene therapy. Cancer Gene Ther, 1994; 1(1):51–64.
9.
GuligP, SwindleS, FieldsM, EisenmanD. A review of clinical trials involving genetically modified bacteria, bacteriophages and their associated risk assessments. Appl Biosaf, 2024; 29(4):186–206; doi: 10.1089/apb.2024.0002
10.
American Society for Gene Therapy. Gene, Cell, & RNA Therapy Landscape Report. 2025.
11.
AtkinsonEM. American Society of Gene Therapy - Third Annual Meeting. IDrugs, 2000; 3(9):1009–1011.
12.
EisenmanD, SwindleS. Food and drug administration guidance on design of clinical trials for gene therapy products with potential for genome integration or genome editing and associated long-term follow-up of research subjects. Appl Biosaf, 2022; 27(4):201–209; doi: 10.1089/apb.2022.0022
13.
EisenmanD, SwindleS. FDA guidance on shedding and environmental impact in clinical trials involving gene therapy products. Appl Biosaf, 2022; 27(3):191–197; doi: 10.1089/apb.2022.0020
14.
Mohd AbasMD, Mohd AsriMF, YusafawiNAS, et al.Advancements of gene therapy in cancer treatment: A comprehensive review. Pathol Res Pract, 2024; 261:155509; doi: 10.1016/j.prp.2024.155509
15.
WilsonJM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab, 2009; 96(4):151–157; doi: 10.1016/j.ymgme.2008.12.016
16.
MarshallE. Gene therapy death prompts review of adenovirus vector. Science, 1999; 286(5448):2244–2245; doi: 10.1126/science.286.5448.2244
17.
SibbaldB. Death but one unintended consequence of gene-therapy trial. Cmaj, 2001; 164(11):1612.
National Institutes of Health. Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) April 2024 amendment effective September 30, 2024, Federal Register, April 5, 2024 (89 fr 24016). NIH: Bethesda, MD; 2024.
21.
BulchaJT, WangY, MaH, et al.Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther, 2021; 6(1):53; doi: 10.1038/s41392-021-00487-6
22.
PetrichJ, MarcheseD, JenkinsC, et al.Gene replacement therapy: A primer for the health-system pharmacist. J Pharm Pract, 2020; 33(6):846–855; doi: 10.1177/0897190019854962
23.
LiY, ZhouS, WuQ, GongC. CRISPR/Cas gene editing and delivery systems for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2024; 16(1):e1938; doi: 10.1002/wnan.1938
24.
EisenmanD. The United States’ regulatory environment is evolving to accommodate a coming boom in gene therapy research. Appl Biosaf, 2019; 24(3):147–152; doi: 10.1177/1535676019854866
25.
TaghdiriM, MussolinoC. Viral and Non-viral systems to deliver gene therapeutics to clinical targets. Int J Mol Sci, 2024; 25(13); doi: 10.3390/ijms25137333
26.
PoddarA, AhmadyF, PrithvirajP, et al.Advances in CRISPR/Cas systems-based cell and gene therapy. Prog Mol Biol Transl Sci, 2024; 208:161–183; doi: 10.1016/bs.pmbts.2024.07.005
XiaX, GuoX. Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies. Front Med (Lausanne), 2023; 10:1310050; doi: 10.3389/fmed.2023.1310050
29.
WangJH, GesslerDJ, ZhanW, et al.Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther, 2024; 9(1):78; doi: 10.1038/s41392-024-01780-w
RossiA, SalvettiA. Integration of AAV vectors and insertional mutagenesis. Med Sci (Paris), 2016; 32(2):167–174; doi: 10.1051/medsci/20163202010
33.
ChancellorD, BarrettD, Nguyen-JatkoeL, et al.The state of cell and gene therapy in 2023. Mol Ther, 2023; 31(12):3376–3388; doi: 10.1016/j.ymthe.2023.11.001
34.
McCartyDM, YoungSMJr, SamulskiRJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet, 2004; 38:819–845; doi: 10.1146/annurev.genet.37.110801.143717
BrownAM, BlindJ, CampbellK, GhoshS. Safeguards for using viral vector systems in human gene therapy: A resource for biosafety professionals mitigating risks in health care settings. Appl Biosaf, 2020; 25(4):184–193; doi: 10.1177/1535676020934917
ZhouK, HanJ, WangY, et al.Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases. Front Mol Neurosci, 2022; 15:988914; doi: 10.3389/fnmol.2022.988914
39.
IssaSS, ShaimardanovaAA, SolovyevaVV, RizvanovAA. Various AAV serotypes and their applications in gene therapy: An overview. Cells, 2023; 12(5); doi: 10.3390/cells12050785
40.
MückeMM, FongS, FosterGR, et al.Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists. J Hepatol, 2024; 80(2):352–361; doi: 10.1016/j.jhep.2023.10.029
41.
PipeS, LeebeekFWG, FerreiraV, et al.Clinical considerations for capsid choice in the development of liver-targeted AAV-Based gene transfer. Mol Ther Methods Clin Dev, 2019; 15:170–178; doi: 10.1016/j.omtm.2019.08.015
42.
CharitidisFT, AdabiE, HoN, et al.CAR gene delivery by T-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms. Adv Sci (Weinh), 2023; 10(35):e2302992; doi: 10.1002/advs.202302992
43.
MiloneMC, O’DohertyU. Clinical use of lentiviral vectors. Leukemia, 2018; 32(7):1529–1541; doi: 10.1038/s41375-018-0106-0
KingwellK. Lentiviral vector gene therapies come of age with two FDA approvals. Nat Rev Drug Discov, 2022; 21(11):790–791; doi: 10.1038/d41573-022-00176-1
46.
BlindJE, McLeodEN, CampbellKJ. Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist. Am J Health Syst Pharm, 2019; 76(11):795–802; doi: 10.1093/ajhp/zxz056
47.
BartoschB, CossetFL. Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther, 2004; 4(4):427–443; doi: 10.2174/1566523043345995
48.
Food and Drug Administration. Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up. Food and Drug Administration; 2020.
49.
CoroadinhaAS. Cancer gene therapy: Development and production of lentiviral vectors for gene therapy. Methods Mol Biol, 2022; 2521:297–315; doi: 10.1007/978-1-0716-2441-8_16
WuX, WakefieldJK, LiuH, et al.Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther, 2000; 2(1):47–55; doi: 10.1006/mthe.2000.0095
53.
SchlimgenR, HowardJ, WooleyD, et al.Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med, 2016; 58(12):1159–1166; doi: 10.1097/jom.0000000000000879
54.
PauwelsK, GijsbersR, ToelenJ, et al.State-of-the-art lentiviral vectors for research use: Risk assessment and biosafety recommendations. Curr Gene Ther, 2009; 9(6):459–474; doi: 10.2174/156652309790031120
55.
CesaniM, PlatiT, LorioliL, et al.Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting. Gene Ther, 2015; 22(6):496–502; doi: 10.1038/gt.2015.10
56.
WolffJH, MikkelsenJG. Delivering genes with human immunodeficiency virus-derived vehicles: Still state-of-the-art after 25 years. J Biomed Sci, 2022; 29(1):79; doi: 10.1186/s12929-022-00865-4
57.
De RavinSS, GrayJT, ThromRE, et al.False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. Mol Ther, 2014; 22(2):244–245; doi: 10.1038/mt.2013.296
58.
van der MeulenK, SmetsG, RüdelsheimP. Viral replicon systems and their biosafety aspects. Appl Biosaf, 2023; 28(2):102–122; doi: 10.1089/apb.2022.0037
59.
BlindJE, McLeodEN, BrownA, et al.Biosafety practices for in vivo viral-mediated gene therapy in the health care setting. Appl Biosaf, 2020; 25(4):194–200; doi: 10.1177/1535676020942195
60.
TrivediPD, ByrneBJ, CortiM. Evolving horizons: Adenovirus vectors’ timeless influence on cancer, gene therapy and vaccines. Viruses, 2023; 15(12); doi: 10.3390/v15122378
61.
SalauddinM, SahaS, HossainMG, et al.Clinical Application of Adenovirus (AdV): A comprehensive review. Viruses, 2024; 16(7); doi: 10.3390/v16071094
62.
Bin UmairM, AkusaFN, KashifH, et al.Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol, 2022; 167(6):1387–1404; doi: 10.1007/s00705-022-05432-8
63.
WoldWS, TothK. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther, 2013; 13(6):421–433; doi: 10.2174/1566523213666131125095046
64.
LeikasAJ, Ylä-HerttualaS, HartikainenJEK. Adenoviral gene therapy vectors in clinical use-basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety. Int J Mol Sci, 2023; 24(22); doi: 10.3390/ijms242216519
65.
SyyamA, NawazA, IjazA, et al.Adenovirus vector system: Construction, history and therapeutic applications. Biotechniques, 2022; 73(6):297–305; doi: 10.2144/btn-2022-0051
66.
YngveE, GaoM, YuD. A qPCR-Based METHOD FOR QUANTIFICATION of Replication Competent Adenovirus (RCA) in conditionally replicating oncolytic adenoviruses. Methods Mol Biol, 2022; 2521:249–258; doi: 10.1007/978-1-0716-2441-8_13
67.
MantwillK, KleinFG, WangD, et al.Concepts in oncolytic adenovirus therapy. Int J Mol Sci, 2021; 22(19); doi: 10.3390/ijms221910522
68.
BlindJE, GhoshS, NieseTD, et al.A comprehensive literature scoping review of infection prevention and control methods for viral-mediated gene therapies. Antimicrob Steward Healthc Epidemiol, 2024; 4(1):e15; doi: 10.1017/ash.2024.1
69.
HavengaMJ, LemckertAA, OphorstOJ, et al.Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol, 2002; 76(9):4612–4620; doi: 10.1128/jvi.76.9.4612-4620.2002
Fausther-BovendoH, KobingerGP. Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother, 2014; 10(10):2875–2884; doi: 10.4161/hv.29594
72.
AhiYS, BangariDS, MittalSK. Adenoviral vector immunity: Its implications and circumvention strategies. Curr Gene Ther, 2011; 11(4):307–320; doi: 10.2174/156652311796150372
73.
AnsonDS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther, 2004; 2(1):9; doi: 10.1186/1479-0556-2-9
74.
SinnPL, SauterSL, McCrayPB.Jr., Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors–design, biosafety, and production. Gene Ther, 2005; 12(14):1089–1098; doi: 10.1038/sj.gt.3302570
75.
CastielloMC, FerrariS, VillaA. Correcting inborn errors of immunity: From viral mediated gene addition to gene editing. Semin Immunol, 2023; 66:101731; doi: 10.1016/j.smim.2023.101731
76.
HirchT, BranderN, SchenkF, et al.Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia. Sci Rep, 2023; 13(1):19386; doi: 10.1038/s41598-023-46332-4
77.
ShchaslyvyiAY, AntonenkoSV, TesliukMG, TelegeevGD. Current state of human gene therapy: Approved products and vectors. Pharmaceuticals (Basel), 2023; 16(10); doi: 10.3390/ph16101416
Hacein-Bey-AbinaS, GarrigueA, WangGP, et al.Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 2008; 118(9):3132–3142; doi: 10.1172/jci35700
80.
HoweSJ, MansourMR, SchwarzwaelderK, et al.Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest, 2008; 118(9):3143–3150; doi: 10.1172/jci35798
81.
Schenk-BraatEA, van MierloMM, WagemakerG, et al.An inventory of shedding data from clinical gene therapy trials. J Gene Med, 2007; 9(10):910–921; doi: 10.1002/jgm.1096
82.
WeissRA. The discovery of endogenous retroviruses. Retrovirology, 2006; 3:67; doi: 10.1186/1742-4690-3-67
83.
ParthasarathyR, WakefieldD, SantiagoFS, et al.Horizontal gene transfer and endogenous retroviruses as mechanisms for molecular mimicry. Lancet Microbe, 2024; 5(1):e4–e5; doi: 10.1016/s2666-5247(23)00316-6
84.
ThomasCE, EhrhardtA, KayMA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet, 2003; 4(5):346–358; doi: 10.1038/nrg1066
85.
ShirleyJL, de JongYP, TerhorstC, HerzogRW. Immune responses to viral gene therapy vectors. Mol Ther, 2020; 28(3):709–722; doi: 10.1016/j.ymthe.2020.01.001
86.
MarconiP, ArgnaniR, BertoE, et al.HSV as a vector in vaccine development and gene therapy. Hum Vaccin, 2008; 4(2):91–105; doi: 10.4161/hv.4.2.6212
87.
FukuharaH, InoY, TodoT. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci, 2016; 107(10):1373–1379; doi: 10.1111/cas.13027
88.
MarconiP, ArgnaniR, EpsteinAL, ManservigiR. HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol, 2009; 655:118–144; doi: 10.1007/978-1-4419-1132-2_10
89.
MarconiP, ManservigiR, EpsteinAL. HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel, 2010; 13(2):169–183.
90.
AldrakN, AlsaabS, AlgethamiA, et al.Oncolytic herpes simplex virus-based therapies for cancer. Cells, 2021; 10(6); doi: 10.3390/cells10061541
91.
KhanA, RiazR, AshrafS, AkilimaliA. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa. Ann Med Surg (Lond), 2023; 85(12):6298–6301; doi: 10.1097/ms9.0000000000001422
92.
EpsteinAL, MarconiP, ArgnaniR, ManservigiR. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther, 2005; 5(5):445–458; doi: 10.2174/156652305774329285
93.
DuebgenM, Martinez-QuintanillaJ, TamuraK, et al.Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst, 2014; 106(6):dju090; doi: 10.1093/jnci/dju090
94.
LimF, KhaliqueH, VentosaM, BaldoA. Biosafety of gene therapy vectors derived from herpes simplex virus type 1. Curr Gene Ther, 2013; 13(6):478–491; doi: 10.2174/156652321306140103224550
95.
AgyemangE, MagaretAS, SelkeS, et al.Herpes simplex virus shedding rate: Surrogate outcome for genital herpes recurrence frequency and lesion rates, and phase 2 clinical trials end point for evaluating efficacy of antivirals. J Infect Dis, 2018; 218(11):1691–1699; doi: 10.1093/infdis/jiy372
96.
KoelleDM, WaldA. Herpes simplex virus: The importance of asymptomatic shedding. J Antimicrob Chemother, 2000; 45(Suppl T3):1–8; doi: 10.1093/jac/45.suppl_4.1
97.
U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Design and Analysis of Shedding Studies for Virus or bacteria-Based Gene Therapy and Oncolytic Products. FDA: 2015.
98.
EpsteinAL, RabkinSD. Safety of non-replicative and oncolytic replication-selective HSV vectors. Trends Mol Med, 2024; 30(8):781–794; doi: 10.1016/j.molmed.2024.05.014
HaoM, HuangC, XiaN. The advances of oncolytic herpes simplex virus in cancer therapy. Bing Du Xue Bao, 2016; 32(4):516–522.
101.
U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 6th ed. 2020.
102.
MondalM, GuoJ, HeP, ZhouD. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother, 2020; 16(10):2389–2402; doi: 10.1080/21645515.2020.1723363
103.
TangC, LiL, MoT, et al.Oncolytic viral vectors in the era of diversified cancer therapy: From preclinical to clinical. Clin Transl Oncol, 2022; 24(9):1682–1701; doi: 10.1007/s12094-022-02830-x
104.
KohlhappFJ, ZlozaA, KaufmanHL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc), 2015; 51(9):549–558; doi: 10.1358/dot.2015.51.9.2383044
105.
ChowaniecH, ŚlubowskaA, MroczekM, et al.New hopes for the breast cancer treatment: Perspectives on the oncolytic virus therapy. Front Immunol, 2024; 15:1375433; doi: 10.3389/fimmu.2024.1375433
106.
BayanCY, LopezAT, GartrellRD, et al.The role of oncolytic viruses in the treatment of melanoma. Curr Oncol Rep, 2018; 20(10):80; doi: 10.1007/s11912-018-0729-3
107.
LaroccaCA, LeBoeufNR, SilkAW, KaufmanHL. An update on the role of talimogene Laherparepvec (T-VEC) in the treatment of melanoma: Best practices and future directions. Am J Clin Dermatol, 2020; 21(6):821–832; doi: 10.1007/s40257-020-00554-8
108.
RiesS, KornWM. ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer, 2002; 86(1):5–11; doi: 10.1038/sj.bjc.6600006
109.
YiL, NingZ, XuL, et al.The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: An open-label, single-arm, pilot study. ESMO Open, 2024; 9(2):102239; doi: 10.1016/j.esmoop.2024.102239
110.
XuL, SunH, LemoineNR, et al.Oncolytic vaccinia virus and cancer immunotherapy. Front Immunol, 2023; 14:1324744; doi: 10.3389/fimmu.2023.1324744
111.
CejalvoJM, FalatoC, VillanuevaL, et al.Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment? Cancer Treat Rev, 2022; 106:102392; doi: 10.1016/j.ctrv.2022.102392
112.
DispenzieriA, TongC, LaPlantB, et al.Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia, 2017; 31(12):2791–2798; doi: 10.1038/leu.2017.120
113.
ZamarinD, PaleseP. Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions. Future Microbiol, 2012; 7(3):347–367; doi: 10.2217/fmb.12.4
114.
SmithKER, PengKW, PulidoJS, et al.A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: Safety, efficacy, and T cell responses. Front Immunol, 2023; 14:1279387; doi: 10.3389/fimmu.2023.1279387
115.
DesjardinsA, GromeierM, HerndonJE2nd, et al.Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med, 2018; 379(2):150–161; doi: 10.1056/NEJMoa1716435
KastangoES. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies. J Parenter Enteral Nutr, 2012; 36(2S):38s–39s; doi: 10.1177/0148607111434779
119.
MullarkeyT. Pharmacy compounding of high-risk level products and patient safety. Am J Health Syst Pharm, 2009; 66(17 Suppl 5):S4–S13; doi: 10.2146/ajhp0108b
120.
KennedyK, VuK, CoakleyN, et al.Safe handling of hazardous drugs. J Oncol Pharm Pract, 2023; 29(2):401–412; doi: 10.1177/10781552221135121
121.
Halioua-HauboldCL, PeyerJG, SmithJA, et al.Regulatory considerations for gene therapy products in the U.S., EU, and Japan. Yale J Biol Med, 2017; 90(4):683–693.
122.
World Health Organization. Laboratory biosafety manual, 4th edition and associated Monographs: Risk Assessment. 2020.
123.
FicocielloB, GiordanoD, IncoronatoF, et al.WHO laboratory biosafety manual: A new approach to security. Ann Work Expo Health, 2023; 67(4):425–429; doi: 10.1093/annweh/wxac086
124.
World Health Organization. Laboratory biosafety manual, 4th edition and associated Monographs: Decontamination and Waste Management. 2020.
125.
World Health Organization. Laboratory biosafety manual, 4th edition and associated Monographs: Biological Safety Cabinets and Other Primary Containment Devices. 2020.
126.
World Health Organization. Laboratory biosafety manual, 4th edition and associated Monographs: Personal Protective Equipment. 2020.
127.
CornettaK, KayS, UrioF, et al.Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther, 2023; 31(9):2561–2565; doi: 10.1016/j.ymthe.2023.07.019
128.
MadabushiR, SeoP, ZhaoL, et al.Review: Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res, 2022; 39(8):1669–1680; doi: 10.1007/s11095-022-03288-w
129.
CornettaK, LinTY, PellinD, KohnDB. Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing. Mol Ther Methods Clin Dev, 2023; 28:28–39; doi: 10.1016/j.omtm.2022.11.009
130.
GuoC, MaX, GaoF, GuoY. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol, 2023; 11:1143157; doi: 10.3389/fbioe.2023.1143157
131.
PengJ, ZouWW, WangXL, et al.Viral-mediated gene therapy in pediatric neurological disorders. World J Pediatr, 2024; 20(6):533–555; doi: 10.1007/s12519-022-00669-4
132.
SwindleS. Biosafety in handling gene transfer vectors. Curr Protoc Hum Genet, 2018; 96:12–12.1.17; doi: 10.1002/cphg.54
133.
KohnDB, ChenYY, SpencerMJ. Successes and challenges in clinical gene therapy. Gene Ther, 2023; 30(10–11):738–746; doi: 10.1038/s41434-023-00390-5
134.
AjslevJZN, MøllerJL, AndersenMF, et al.The hierarchy of controls as an approach to visualize the impact of occupational safety and health coordination. Int J Environ Res Public Health, 2022; 19(5); doi: 10.3390/ijerph19052731
135.
EisenbergS. NIOSH Safe handling of hazardous drugs guidelines becomes state law. J Infus Nurs, 2015; 38(Suppl 6):S25–S8; doi: 10.1097/nan.0000000000000141
136.
U.S. Department of Health and Welfare, National Institutes of Health. Laboratory Safety Monograph: A Supplement to the NIH Guidelines for Recombinant DNA Research Prepared by the Office of Research Safety, National Cancer Institute and the Special Committee of Safety and Health Experts 1/2/79.
137.
VitranoG, MicheliGJL. Effectiveness of occupational safety and health interventions: A long way to go. Front Public Health, 2024; 12:1292692; doi: 10.3389/fpubh.2024.1292692
138.
National Research Council Committee on Hazardous Biological Substances. Biosafety in the Laboratory: Prudent Practices for the Handling and Disposal of Infectious Materials. National Academies Press (U.S.): Washington, DC; 1989.
